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Current perspectives
Disaggregating asthma: Big investigation versus
big data
Danielle Belgrave, PhD,a John Henderson, MD,b Angela Simpson, MD, PhD,c Iain Buchan, MD, PhD,d
Christopher Bishop, PhD,e and Adnan Custovic, MD, PhD, FAAAIa London, Bristol, Manchester, and Cambridge,
United Kingdom
We are facing a major challenge in bridging the gap between
identifying subtypes of asthma to understand causal mechanisms
and translating this knowledge into personalized prevention and
management strategies. In recent years, ‘‘big data’’ has been sold
as a panacea for generating hypotheses and driving new frontiers
of health care; the idea that the data must and will speak for
themselves is fast becoming a new dogma. One of the dangers of
ready accessibility of health care data and computational tools for
data analysis is that the process of data mining can become
uncoupled from the scientific process of clinical interpretation,
understanding the provenance of the data, and external
validation. Although advances in computational methods can be
valuable for using unexpected structure in data to generate
hypotheses, there remains a need for testing hypotheses and
interpreting results with scientific rigor. We argue for combining
data- and hypothesis-drivenmethods in a careful synergy, and the
importance of carefully characterized birth and patient cohorts
with genetic, phenotypic, biological, and molecular data in this
process cannot be overemphasized. The main challenge on the
road ahead is to harness bigger health care data in ways that
produce meaningful clinical interpretation and to translate this
into better diagnoses and properly personalized prevention and
treatment plans. There is a pressing need for cross-disciplinary
research with an integrative approach to data science,
whereby basic scientists, clinicians, data analysts, and
epidemiologists work together to understand the heterogeneity of
asthma. (J Allergy Clin Immunol 2017;139:400-7.)
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A major obstacle to realizing precision (stratified or personal-
ized) medicine in asthmatic patients is the lack of consensus in
defining the disease, which is, at least in part, a consequence of
‘‘asthma’’ being an aggregated diagnosis comprising several
different diseases.1-4 It is now well established that both
asthma3,5-8 and allergic sensitization9-12 are umbrella terms (or
syndromes) incorporating a variety of underlying endotypes
sharing common symptoms and phenotypic characteristics.13,14
Although by definition each endotype has unique pathophysi-
ology and hence genetic and environmental associations,13,14 it
is likely that some mechanisms overlap 1 or more endotypes.15
This underlying heterogeneity is also reflected in responses to
treatment. For example, a therapeutic agent might be specific
for a pathway that is primarily responsible for the patient’s asthma
subtype, and therapeutic response can be predicted reasonably
well by using relevant biomarkers,16,17 such as the number of
eosinophils in peripheral blood or sputum for mepolizumab18 or
periostin levels for lebrikizumab.19 Alternatively, a therapeutic
agent might be relatively nonspecific and target broad mecha-
nisms shared between different asthma endotypes, in which
case patients across different endotypes might display a spectrum
of responses, which is likely the case with inhaled corticosteroids.
Across different disease areas, a vast number of genetic
studies have initially raised expectations over ‘‘significant hits’’
that later delivered neither meaningful clinical diagnostic tools
nor useful insights into disease pathogenesis.20 Genetic studies
have thus far explained little of the heritability of complex dis-
eases.21 Associated genetic variants generally have small effect
sizes, and for many of these genetic variants, there is a lack of
clear functional implication. In addition to gene-environment
interactions,22 gene-environment correlations,23 and epigenetic
mechanisms,24 the use of aggregated definitions of disease can
also contribute to inconsistent findings between studies
investigating genetic components of asthma. However, by using
more specific phenotyping, a recent genome-wide association
study identified an association of a specific asthma subtype char-
acterized by early-life onset and recurrent severe exacerbations at
preschool age, with a functional variant in the novel susceptibility
gene CDHR3 (rs6967330, C529Y).25 This genetic variant was
associated with a greater risk of asthma hospitalizations in 2 birth
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Abbreviation used
STELAR: Study Team for Early Life Asthma Research
cohorts, but there was no association with an aggregated
definition of ‘‘doctor-diagnosed asthma.’’ Subsequent studies
have shown that expression of human CDHR3 facilitates
rhinovirus C binding and replication and that a coding single
nucleotide polymorphism in CDHR3, which was linked with
asthma hospitalizations in birth cohort studies, mediates
enhanced rhinovirus C binding and increased progeny
yields in vitro.26 It is also of note that when asthma was
disaggregated into subtypes, much stronger associations were
observed for some of the genetic variants previously identified
in genome-wide association studies, such as those in the 17q21
locus.25 The value of focusing on specific subgroups has
been demonstrated in a study that showed that variants at
17q21 were associated with asthma but only in children
who had rhinovirus-induced wheezing illness.27 Similarly, the
risk of transient early wheeze, but not persistent wheeze,
increases with the number of chronic obstructive pulmonary
disease–associated alleles.28 Most of the genetic studies that
used more precise phenotypes showed higher relative risk
estimates than the modest effect sizes of genetic hits that were
identified by using a simple binary trait definition of asthma,
highlighting the need for a more refined subtyping of asthma to
accurately identify genetic variants of clinical importance.29
Many environmental exposures are implicated in the
development of asthma and in determining its severity.30,31 As
with genetic associations, there have been many inconsistent
reports about the role of environmental exposures in asthmatic
patients. We and others have shown that different phenotypes of
childhood wheezing have different environmental associa-
tions.2,8,32-38 Similarly, different subtypes of atopic sensitization
differ in their environmental risk factors; for example, endotoxin
exposure is protective for multiple early but not multiple late
sensitizations.39 It is likely that the effect of most environmental
factors varies across subjects with different genetic predisposi-
tions, but the precise nature of most gene-environment
interactions remains unclear.22 One of the most replicated
findings of gene-environment interactions in the development of
allergic sensitization is between CD14 variants and environ-
mental endotoxin exposure.40 Several studies have reported that
high endotoxin exposure can protect against sensitization but
only among subjects with a specific genetic predisposition
(C allele homozygotes of rs2569190).40,41 However, in the
same genotype group the effect of endotoxin exposure differed
by phenotype, decreasing the risk of atopic sensitization
and eczema but increasing the risk of nonatopic (but not
atopic) wheezing.41 Other examples that the nature of gene-
environment interactions can differ between different wheeze
phenotypes include the finding that day care attendance can
have opposite effects on atopic wheezing among subjects with
different genetic variants in the Toll-like receptor 2 gene (being
protective in some but increasing the risk in others),42 with no
such effect being observed for nonatopic wheezing.42 This
suggests that replication of gene-environment interactions can
be improved through a more precise definition of the outcome
of interest.43 The lessons for intervention studies aimed at
personalized prevention is that individual genetic predisposition
must be taken into account when seeking the environmental
protective/susceptibility factors amenable to intervention30 and
that interventions that might be effective in one subtype of
wheezing might not necessarily work for other subtypes.
One area that has been relatively more successful is the
identification of biomarkers16 for more targeted treatment
strategies.17 A recent review Berry and Busse44 identified 4
main biomarkers that might help optimize treatment strategies
for different asthma phenotypes. These biomarkers are generally
limited to T2 mechanisms: eosinophils, exhaled nitric oxide,
periostin, and IgE. However, biomarker assessment has not as
yet become an integral part of clinical practice, nor is it reflected
in current asthma guidelines. Validation steps are necessary, and
acknowledgement in asthma guidelines would prompt
application of such information in clinical practice. The
identification of non-T2 biomarkers is an important area of
research that needs to be exploited44 with biomarker identification
for asthma and allergic diseases still in its embryonic stages.
Furthermore, although biomarker identification has indeed led
to more targeted asthma treatment strategies, there are currently
no biomarkers that reflect the underlying causal mechanisms,
which could predict disease onset or progression.
Although phenotypic heterogeneity of asthma is now widely
accepted, we are still scratching the surface of identifying the
different endotypes of asthma and understanding their unique
underlying pathophysiologic mechanisms, which is a prerequisite
for precisionmedicine.15 Although there is general consensus that
there are different asthma endotypes and different phenotypes of
wheezing during childhood, there is no consensus on how best to
define them. A more refined endotypic definition of asthma and
allergic diseases can drive more targeted research to identify
distinct molecular, genetic, environmental, and demographic
characteristics that might allow us to predict causality of distinct
endotypes with greater accuracy.45
One approach used in a number of studies has been to
investigate temporal patterns of symptoms over time. The
common labels across most studies have been transient early
wheeze, late-onset wheeze, and persistent wheeze.46 However,
different studies reported different numbers of childhood wheeze
phenotypes (eg, ranging between 2 and 6).2,46,47 One of the
challenges in current research aimed at defining subgroups of
patients based on the natural history of wheezing is the lack of
consistency in definition of these phenotypes and what they
represent. The inconsistency in defining wheeze phenotypes
based on longitudinal profiles of symptoms over time across
different studies might merely reflect inconsistencies in the nature
and timing of questions used (eg, physician-confirmed
wheezing8,34 vs parentally reported wheezing6,36). Thus although
the definition of subtypes based on profiles of symptoms over time
is better than that based on a single time point, variability in input
variables has an effect on the accuracy of defining subtypes and
identifying predictive models.2,47-49
CAN ‘‘BIG DATA’’ PROVIDE SOLUTIONS?
Big data refers not only to the ready availability of large
volumes of routine health care data being rapidly generated but
also to the complexity of these data, which is evident in the
amplified scale of biological, genetic, environmental, and
phenotypic data. The scale of these data often makes handling,
management, and analysis challenging with the use of standard
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statistical methods. The evolution of powerful computational
tools to analyze such high-dimensional large data sets has pushed
the boundaries of endotype discovery. Such data provide the
potential for ‘‘learning’’ patterns or predicting health outcomes
and optimal treatment strategies based on prior information.
However, one of the major challenges of big data remains the bias
inherent to its volume. Furthermore, the vast increase in the
quantity of data generated hasmade it impossible at times to know
for what we are looking and what questions need to be asked. As a
consequence, data-driven hypothesis-generating approaches to
understanding disease are overshadowing traditional hypothesis-
based research (hypothesis testing) through carefully constructed
questions and observations. In a hypothesis-generating approach
to data analysis, we look for structure in the data without
necessarily having a specific research hypothesis we want to
verify. This is an advantage where, for example, we have
measures of multiple biomarkers but are uncertain of the role of
these biomarkers in predicting asthma. A hypothesis-generating
approach can be used to identify patterns in biomarkers (eg, which
ones are similar or which ones modify the effect of other
biomarkers) to predict the disease. In recent years, big data has
been sold as a panacea for generating hypotheses and driving new
frontiers of health care; the idea that the data must and will speak
for themselves is fast becoming a new dogma. However, we argue
for combining data-driven and hypothesis-driven methods in
careful synergy.
ON METHODOLOGIES: UNDERSTANDING REALITY
VERSUS PREDICTING THE FUTURE
Machine learning, computational statistics, biostatistics, a
traditional approach to epidemiology, and clinical and biological
expertise can elucidate different aspects of the same problem.
Machine learning is a data-driven approach to identify structure
within data to make predictions and identify patterns. It is used
commonly by computer scientists for problem solving in a variety
of fields and is used increasingly to disaggregate complex disease
phenotypes in respiratory medicine and allergy.1,3,5,10-12 It must
be noted that although machine learning as a discipline is fairly
new, the mathematic and statistical foundations have been in ex-
istence since the beginning of the 20th century.50-53 Machine
learning as a new discipline is a result of the exponential growth
in computational power, which has enabled implementation of the
mathematic groundwork that was initiated decades earlier.54,55
One of the (somewhat artificial) distinctions between machine
learning and conventional statistical approaches is that although
machine learning focuses on prediction models and attempts to
accurately predict future outcomes/events (whether these be
future disease states or the development of symptoms in later
life), statistics tends to focus on extant observations and
constructing models to aid understanding of the data and the
current status of disease. Hence statistics tends to focus on
causality and associations in an attempt to explain the disease and
to understand uncertainty in the modelling assumptions.
Modelling assumptions refers to our framework for represent-
ing the data or research questions related to that data. Because
these are assumptions, we are uncertain about them and need
someway of testing whether these assumptions are true. Machine
learning applied to medicine attempts to predict disease states and
to get the best estimate of uncertainty analogous to clinical
diagnosis. Both approaches combined with epidemiology, which
carefully tests hypotheses to infer causality, need to be considered
along with medical and biological expertise in a holistic
understanding of disease.
BAYESIAN VERSUS FREQUENTIST APPROACH TO
UNDERSTANDING DISEASE ETIOLOGY
We now introduce the reader to 2 different approaches to
hypothesis testing and hypothesis generation: the Bayesian and
frequentist approaches. The aim of this discussion is to provide a
conceptual framework that is currently commonly used in statis-
tical and machine learning and can be applied to both big and
small data sets in health care research. An understanding of these
2 paradigms is formative for a team approach to understanding
disease etiology in health care.
The frequentist paradigm is an unconditional perspective,
meaning that it assumes that the observed data are representative
of the population with an independent and identical distribution.
Thus this paradigm, as the name suggests, emphasizes the
frequency of the data. On the other hand, the Bayesian approach
uses probability as a principled framework for quantifying our
uncertainty of the data and of the true estimated effects in our
models, thereby allowing the explicit incorporation of prior
scientific knowledge into statistical reasoning. Bayesian models
provide a framework whereby prior knowledge and data from
previous studies can be incorporated explicitly with the data at
hand in the analytic model to formulate a posterior distribution
that takes account of both the observed data and prior knowl-
edge.56 The inherent characteristics of the Bayesian approach to
data analysis make this framework more amenable to handling
large-scale problems and easily extending the complexity of cur-
rent models that use classical statistical or frequentist tools.
Although the frequentist approach also relies on prior clinical
knowledge, the difference is that this approach does not seek to
explicitly quantify this knowledge; it only relies on the data at
hand for incorporating assumptions we make about the statistical
models for the data.
In understanding the etiology of asthma and allergic disease,
Bayesian models provide a flexible and unified framework for
understanding the probability of disease manifestation and
comanifestation, incorporating evidence from the literature or
hypotheses from medical experts5 through the explicit
quantification of this evidence. However, although Bayesian
methods provide an intuitive and unified platform for carrying
out statistical research, the results are often computationally
intractable and resolving these is active area of research.57-60
The exponential increase in computational power and the
increasing availability of tools that can handle large-scale data
has facilitated the use of Bayesian methods, and it is important
that we capitalize on these relatively complex tools to improve
human health.
The use of Bayesian statistics is relatively uncommon in the
medical literature, in part because of the greater complexity
involved in using these models. One of the strengths of the
Bayesian approach is that it can be used to enrich our current
understanding of disease, with its capacity to elicit robust
scientific inference by encouraging the user to think about the
underlying statistical and scientific problems61 by assigning
explicit quantities to scientific assumptions. This might provide
a powerful tool for extending model complexity to reflect the
underlying complexity of the data and the scientific problem
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being addressed. Bayesian methods allow the clinician to take an
active role in the modelling process by quantifying prior probabil-
ities based on expert assessments. However, one limitation of
Bayesian analysis is the difficulty in eliciting this prior knowledge
and quantifying expert knowledge,62,63 mainly because pf the
training and time necessary to develop ‘‘informative’’ prior
knowledge. In some cases this can be more expensive than col-
lecting more data. This approach is not unique to Bayesian anal-
ysis. Prior knowledge can be integrated to a less explicit degree by
using a frequentist platform, where, rather than specifying or
quantifying expected results, a clinician/topic expert could
specify explicit assumptions about expected transitions of allergic
disease and symptom profiles, as well as the proportions of pa-
tients with different profiles and severities of disease. In this sense
the often-acclaimed advantage of Bayesian analysis as being able
to incorporate informative prior knowledge based on expert
knowledge may be overstated. The frequentist approach can be
used to compare different model assumptions based on expert
knowledge, which might be a more pragmatic approach than
trying to quantify uncertainty surrounding the size of an effect.
The important take-home message is that in weighing up the
Bayesian and frequentist approach to statistical modelling, the
question is not so much which method is best but rather which
method is more appropriate for the question being addressed
and for encapsulating model complexity with parsimony.64
AWAY FROM METHODOLOGICAL POLEMICS
TOWARD DATA SCIENCE
This dissonance between machine learning, biostatistics, and
epidemiology on the one hand and between the Bayesian and
frequentist paradigms on the other presents artificial dichotomies.
Beyond the methodological dogma, science needs to be
pragmatic, selecting the right method or methods for the
problem/question. Different methodologies are not mutually
exclusive; indeed, an ensemble of methods might be more
effective for identifying distinct subtypes of diseases. Data
sciencemust take the path of least inferential resistance, including
the use of better ways to incorporate prior knowledge about likely
causal mechanisms.
LATENT VARIABLE MODELLING APPROACH TO
UNDERSTANDING SUBTYPES OF DISEASE
A general area in which Bayesian and frequentist paradigms
compete (or complement) is latent variable modelling.65 This sec-
tion highlights the importance of latent variable modelling as a
generalized framework for hypothesis generating and dimension-
ality reduction. Dimensionality reduction is an important tool for
analysis of big data, inwhichwehavemultiple clinical,molecular,
genetic, environmental, and phenotypic elements (ie, high dimen-
sions). As the name suggests, in dimensionality reduction the aim
is to reduce the dimension of the data set to a more manageable
group of meaningful variables. Latent variable modelling can
also be used not just to reduce the dimension of variables within
a large data set but also to identify subgroups of patients based
on patterns within these variables. Latent variable models are
increasingly cited in the medical literature66-68 for classifying
different phenotypes and subphenotypes of diseases based on in-
dividual disease profiles. The latent variable model is a statistical
model in which the observed association between (manifest)
observed variables is regarded as spurious because this observed
association can be explained by an indirectly observed, hidden,
or latent variable rather than being causally related. This provides
a powerful approach to probabilistic modelling and offers a
flexible method to investigate substructures within complex data
sets, in which associations between a set of observed variables
are supplemented with additional latent variables. Therefore
latent variable modelling allows us to move from hypothesis
testing to hypothesis generation.69 A further advantage of using
latent variable modelling is that it is easier to represent
high-dimensional parameters70-73 on a reduced space with fewer
dimensions. For example, using such techniques, we can reduce
the dimensionality of multiple continuous variables into a more
manageable set with fewer variables (parameters). The reduced
number of variables is representative of a larger data set. Reducing
dimensionality onto a latent space in turn facilitates the
interpretation of multiple correlated continuous factors. The use
of Bayesian methods in this context complements the
likelihoods from the data with prior hypotheses about the
expected distribution of these latent variables. We have
successfully used generalized latent variable modelling
approaches to identify distinct subtypes of asthma2,3,6,9-12,15,34,36
and allergic diseases.5,9,11,12 The key to future discoveries is to
uncover underlying pathophysiologic mechanisms (endotypes)
that drive these distinct subtypes.1
BIG DATA WITH BIG PROMISES: THE
CONTRIBUTION OF COHORTS TO OUR
UNDERSTANDING OF ASTHMA
The public’s expectation that their health data should be used to
improve care services has sometimes been stalled by fears over
privacy and unregulated commercial uses of the data.74 Birth
cohort studies are an interesting parallel because cradle-to-
grave health care records can be thought of in this way. However,
unlike routine health care records, birth cohorts make more
systematic observations before the onset of disease, facilitating
exploration of the natural history of disease. With data from birth
cohorts, investigators can follow development of disease over
time, which mimics clinicians’ diagnoses and follow-up
observations but in a more anticipatory way.
One initiative aimed at harnessing data from birth cohorts to
understand the development of different endotypes of asthma and
allergic diseases is the Study Team for Early Life Asthma
Research (STELAR) consortium.15 STELAR combines data
from 5 United Kingdom birth cohorts aimed at understanding
the development of asthma and allergic diseases through the
life course. The cohorts include the Avon Longitudinal Study of
Parents and Children, Ashford cohort, Isle of Wight cohort,
Manchester Asthma and Allergy Study, and Aberdeen Study of
Eczema and Asthma to Observe the Effects of Nutrition.
STELAR has data on more than 14,000 participants with repeated
measures on symptoms of asthma and allergy over multiple time
points from childhood into adulthood. An important feature is that
participants are sampled from the general population, enabling
generalizable conclusions about the pathophysiology and
development of asthma at large. This would be difficult with
routine health care records because they have more selected/
biased observations sampled later in the natural history of disease.
Fig 1 summarizes the challenges in understanding asthma and
allergic disease that will drive future research in the STELAR
consortium.
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An important area in which recent cohort studies have
elucidated pathways for development of asthma into fixed airway
obstruction is in investigating longitudinal profiles of lung
function.75-77 Such profiles can shed light on the causes and
consequences of airway obstruction that provide us with an
objectivemarker of airway disease, which can be easily translated
into clinical practice.
We consider that clinical/case (patient) cohorts and birth
cohorts provide complementary windows on different aspects of
understanding disease etiology.78 An important and largely
unanswered question is how best to translate findings between
case and birth cohorts (ie, between clinical and general
populations) to inform better prevention and early intervention
strategies.79 The case has been argued for automated methods
to update disease models in real time.80-84 The technologies are
available, but they have not been applied in this way to
accelerate the translation of research findings into clinical
practice nor have they been used to enrich research models with
emergent clinical phenomena. The importance of carefully
characterized birth and patient cohorts with genetic, phenotypic,
biological, environmental, and molecular data cannot be
overemphasized in the quest to understand asthma and discover
its endotypes.
CONCLUSION: THE IMPORTANCE OF TEAM
SCIENCE
We are facing a major challenge to bridge the gap between
identifying subtypes of asthma in clinical and general populations
(and to find ways to translate the findings between these 2
contexts) to understand causal mechanisms of the discovered
subtypes and translating this knowledge into better prevention
and management strategies.78,85 To this effect, understanding dis-
ease causality within the data analytic framework is fundamental
to improve our understanding of asthma endotypes and their
distinct etiologies.86 From this perspective, significant investment
needs to be made in advancing statistical and computational tools
to solve health care problems. However, although advances in
computational methods can be valuable for identifying
unexpected structure in data to generate hypotheses, there
remains a need for interpreting results with scientific rigor and
testing hypotheses that arise from this process. One of the dangers
of ready accessibility of health care data and computational tools
for analyzing these data is that the process of data mining can
become uncoupled from the scientific process of clinical
interpretation, understanding the provenance of the data, and
external validation.87 There is a pressing need for cross-
disciplinary research to avoid the false idol of big data being
the single source of truth. A more credible approach is to blend
big data with big reasoning, so that prior structure is imposed
on the datameaningfully. Fig 2 illustrates a data cycle encompass-
ing the problem: an integrative approach to data science whereby
basic scientists, clinicians, biostatisticians, and epidemiologists
work together to understand the heterogeneity of asthma and
allergic disease. Given that big data takes team science, it would
be important for the scientific and academic communities to reas-
sess systems and criteria for promotion that still, in many cases,
do not give sufficient credit for perceived nonleadership roles.
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We need to ensure that we harness bigger health care data in
ways that produce meaningful clinical interpretation and to
translate the findings into better diagnoses, biomarkers, and
properly personalized prevention and treatment plans. As an
example, big data could be used to identify patients with
exacerbations and inadequately controlled asthma and then
prompt evaluation of their treatment regimen.17 One of the
advantages of big data is its capacity to change the way we
currently do clinical research in asthma through building more
robust predictive models to understand subtypes of this complex
disease. The direction needs to move away from looking at
average effects (which is a strategy commonly used in
randomized clinical trials that make use of stringent exclusion
criteria as their modelling framework). We advocate that research
into causal biomarker identification and optimal management and
prevention strategies needs to be anchored in understanding of the
underlying disease heterogeneity.
It is important that we, as a community of health
care professionals, work toward transferring evidence-based
information to better patient care. Therefore clinical practitioners
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FIG 2. Data cycle: an integrative approach to understanding disease endotypes.
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should be aware of the need to treat asthma and other
heterogeneous diseases in a more personalized manner and be
ready to incorporate the discovered stratified medicine strategies
in a timely fashion.
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